A Phase 2/3, Multicenter, Multinational, Open Label Study to Evaluate the Efficacy and Safety of ALXN1101 in Neonates With Molybdenum Cofactor Deficiency (MOCD) Type A

Trial Profile

A Phase 2/3, Multicenter, Multinational, Open Label Study to Evaluate the Efficacy and Safety of ALXN1101 in Neonates With Molybdenum Cofactor Deficiency (MOCD) Type A

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs Cyclic pyranopterin monophosphate (Primary)
  • Indications Molybdenum cofactor deficiency
  • Focus Therapeutic Use
  • Sponsors Alexion Pharmaceuticals
  • Most Recent Events

    • 25 Sep 2017 This trial has been Suspended in Spain, according to European Clinical Trials Database
    • 18 Aug 2017 Status changed from recruiting to active, no longer recruiting.
    • 03 Feb 2016 According to an Alexion Pharmaceuticals media release, status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top